Rivaroxaban-d4 (CAS 1132681-38-9)
See product citations (3)
QUICK LINKS
Rivaroxaban-d4 is a chemically modified version of rivaroxaban, where four hydrogen atoms are replaced by deuterium, a stable isotope of hydrogen. n mass spectrometry, Rivaroxaban-d4 can be used as an internal standard. Because of its deuterated atoms, it has a slightly different mass compared to the non-deuterated rivaroxaban, allowing it to be distinguished easily in mass spectrometric analysis. This is for quantifying the amount of rivaroxaban in a sample with high precision and accuracy. In NMR studies, Rivaroxaban-d4 can help in elucidating the molecular structure and dynamics of rivaroxaban. The deuterium atoms provide different NMR signals compared to regular hydrogen, aiding in more detailed structural analysis. In stability studies, Rivaroxaban-d4 can be used to track the degradation of rivaroxaban under various conditions. Its distinct physical properties make it easier to monitor changes over time, contributing to understanding the stability of the molecule.
Rivaroxaban-d4 (CAS 1132681-38-9) References
- Is anti-factor Xa chromogenic assay for Rivaroxaban appropriate in clinical practice? Advantages and comparative drawbacks. | Bardy, G., et al. 2015. Thromb Res. 136: 396-401. PMID: 26058941
- Rivaroxaban transfer across the dually perfused isolated human placental cotyledon. | Bapat, P., et al. 2015. Am J Obstet Gynecol. 213: 710.e1-6. PMID: 26164691
- Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS). | Derogis, PB., et al. 2017. PLoS One. 12: e0171272. PMID: 28170419
- Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. | Gulilat, M., et al. 2017. Can J Cardiol. 33: 1036-1043. PMID: 28754389
- Dosing-time-dependent effect of rivaroxaban on coagulation activity in rats. | Fujiwara, Y., et al. 2017. J Pharmacol Sci. 134: 234-238. PMID: 28844423
- Liquid chromatography-tandem mass spectrometry method for determination of rivaroxaban in human plasma and its application to a pharmacokinetic study. | Shaikh, K., et al. 2020. Eur J Mass Spectrom (Chichester). 26: 91-105. PMID: 31514543
- Rivaroxaban Concentration in Breast Milk During Breastfeeding: A Case Study. | Saito, J., et al. 2019. Breastfeed Med. 14: 748-751. PMID: 31746638
- A simple and sensitive HILIC-based UHPLC-MS/MS method for quantifying of rivaroxaban in dried blood spots: Application in comparison with the plasma sample method. | Iqbal, M., et al. 2021. J Pharm Biomed Anal. 198: 114023. PMID: 33744464
- Development and validation of an ultra-high performance liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of direct oral anticoagulants in human plasma. | Zhang, YF., et al. 2021. J Chromatogr B Analyt Technol Biomed Life Sci. 1182: 122952. PMID: 34598085
- Explaining dissolution properties of rivaroxaban cocrystals. | Hriňová, E., et al. 2022. Int J Pharm. 622: 121854. PMID: 35623488
- Determination of rivaroxaban in rat plasma by ultra-high-performance liquid chromatography-Q-Orbitrap high-resolution mass spectrometry and its application to a pharmacokinetic study. | Qian, J., et al. 2022. Biomed Chromatogr. 36: e5491. PMID: 36003022
- Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: The impact of plasma concentration on clinical outcomes. | Wang, Z., et al. 2022. Thromb Res. 218: 189-191. PMID: 36087354
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rivaroxaban-d4, 1 mg | sc-219982 | 1 mg | $388.00 |